Pharmacokinetics and Pharmacodynamic Effect of a Blood-Brain Barrier-Crossing Fusion Protein Therapeutic for Alzheimer’s Disease in Rat and Dog
Étienne Lessard(Elekta (Sweden)), Balu Chakravarthy(Aditya Birla (India))
Cited by 12
Related Papers
Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
|PubMed|1999|177
Erythromycin Blocks the Rapid Component of the Delayed Rectifier Potassium Current and Lengthens Repolarization of Guinea Pig Ventricular Myocytes
|Circulation|1995|99
Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.
|Pharmacogenetics|2003|94
Diphenhydramine Alters the Disposition of Venlafaxine Through Inhibition of CYP2D6 Activity in Humans
|Journal of Clinical Psychopharmacology|2001|90